People: Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
20 May 2013
Price Change (% chg)

$0.01 (+0.38%)
Prev Close
$2.60
Open
$2.61
Day's High
$2.61
Day's Low
$2.61
Volume
100
Avg. Vol
16,182
52-wk High
$3.99
52-wk Low
$1.97

Search Stocks

Summary

Name Age Since Current Position

Ronald Denis

 Independent Chairman of the Board

Tina Sampalis

 President

Henri Harland

 Chief Executive Officer, Director

Xavier Harland

 2011 Chief Financial Officer

Pierre Lemieux

 2010 Chief Operating Officer

Harlan Waksal

 59 2011 Executive Vice President - Business and Scientific Affairs

Michel Chartrand

 2008 Independent Director

Martin Godbout

 2011 Independent Director

Marc Lebel

 58 2011 Independent Director
» Insider Trading

Biographies

Name Description

Ronald Denis

 Dr. Ronald Denis serves as an Independent Chairman of the Board of Acasti Pharma Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Tina Sampalis

Henri Harland

 Mr. Henri Harland serves as Chief Executive Officer and Director of Acasti Pharma Ltd. Mr. Harland is an Actuary and holds a MBA (Finance) from Laval University. Mr. Henri Harland has been a director as well as the President and Chief Executive Officer of Neptune since its incorporation on October 9, 1998. He is the founder of the Corporation and of Neptune and has been involved in the krill research project since 1991. For more than ten years he has held the position of President and Chief Executive Officer of Gestion Harland Inc., a financial engineering group. Previously, he acted as an independent financial consultant for companies in different industrial sectors in both North America and Europe guiding them through recapitalization, financing and business development.

Xavier Harland

Pierre Lemieux

Harlan Waksal

 Dr. Harlan W. Waksal, M.D., serves as Executive Vice President - Business and Scientific Affairs of Acasti Pharma Inc., since July 2011. Dr. Waksal is a physician and co-founder of ImClone System Inc., where he was instrumental in the development of, and obtaining FDA approval for, a biologic cancer therapy.

Michel Chartrand

 Mr. Michel Chartrand serves as Chief Operating Officer, Director of Acasti Pharma Inc. Before joining the Corporation, he was the Vice-President of Retail Partner Solutions at McKesson Canada between 2009 and 2011. From 2004 to 2009 Mr. Chartrand was the President and Chief Executive Officer of Groupe PharmEssor inc. which included, due to a merger, Gestion Santé Services Obonsoins Inc. and Groupe Essaim Inc., two important Québec pharmacy franchisors in Québec. From 1998 to 2004, Mr. Chartrand was the Executive Vice President of Gestion Santé Services Obonsoins Inc.

Martin Godbout

 Dr. Martin Godbout, Ph.D., serves as an Independent Director of Acasti Pharma Inc. He holds a B.Sc. in Biochemistry (1979) and a doctorate in physiology and molecular endocrinology from Laval University. From 1985 to 1990, he received a postdoctoral fellowship from the Medical Research Council of Canada (MRC) and went to San Diego, California, where he continued research work in molecular neurobiology at the Scripps Research Institute. From May 1994 to May 1997, he was President and CEO of Innovatech Québec, a technology investment fund of 60 million dollars. In May 1997, he became Vice-President of BioCapital, a Canadian venture fund specialized in private financing of start-up companies demonstrating potential in the areas of health and biotechnology. From 200 to 2009 he was President of Genome Canada. Mr. Godbout is an Officer of the Order of Canada (2005). Since 2004, Mr. Godbout is a director of MethylGene, a public company listed on the TSX Exchange. Mr. Godbout is currently a director on several boards of high technology companies, foundations and scientific organizations such as AmorChem, AngioChem, Asmacure, BioContact Québec, Génome Québec, BioQuébec, Montréal In Vivo, Fonds de Recherche Québec-Santé and the Ataxia Charlevoix Foundation.

Marc Lebel

 Dr. Marc Lebel, Ph.D., serves as an Independent Director of Acasti Pharma Inc. Mr. LeBel is the co-founder of Anapharm, a Phase I contract research organization, that reached 1 200 employees. Mr. LeBel was Executive Vice-President of Pharmanet, from 2005 to 2007, following its acquisition of Anapharm. Mr. LeBel is currently Interim CEO and Director of Warnex Inc. His recent venture in the film industry made him Executive Producer “Ruby McCollum”, and Associate Producer of the 3D animation movie “Sarila”. He received the following honors: Excelsia 2006 BioQuébec, Grand Diplômé Université Laval, and Leadership Prize, Canadian Society Pharmaceutical Sciences.

Basic Compensation

Name Fiscal Year Total

Ronald Denis

 --

Tina Sampalis

 442,825

Henri Harland

 377,540

Xavier Harland

 297,915

Pierre Lemieux

 314,767

Harlan Waksal

 276,564

Michel Chartrand

 --

Martin Godbout

 --

Marc Lebel

 --
As Of 28 Feb 2012

Options Compensation

Name Options Value

Ronald Denis

 0 0

Tina Sampalis

 0 0

Henri Harland

 0 0

Xavier Harland

 0 0

Pierre Lemieux

 0 0

Harlan Waksal

 0 0

Michel Chartrand

 0 0

Martin Godbout

 0 0

Marc Lebel

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks